Intravitreal bevacizumab (Avastin) as a treatment of the neovascular complications of laser-induced chorioretinal anastomosis for nonischaemic central retinal vein occlusion

Clinical and Experimental Ophthalmology

Volumn 37, Issue 5, 2009, Pages 485-489

  Fong, Kenneth C S ^a,b   Barry, Chris ^a   Mcallister, Ian L ^a  

^a LIONS EYE INSTITUTE   (Australia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Bevacizumab; Central retinal vein occlusion; Laser induced chorioretinal anastomosis; Neovascular complications

Indexed keywords

BEVACIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CASE REPORT; CENTRAL RETINA VEIN OCCLUSION; DISEASE DURATION; DRUG EFFICACY; DRUG INDICATION; FEMALE; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; MALE; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY;

AGED, 80 AND OVER; ANASTOMOSIS, SURGICAL; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROID; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; LASER COAGULATION; MALE; MIDDLE AGED; RETINAL NEOVASCULARIZATION; RETINAL VEIN; RETINAL VEIN OCCLUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 67651160427     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2009.02063.x     Document Type: Article

References (12)

1. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996; 114: 1243-7.
2. Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for central retinal vein occlusion: An evidence-based systematic review. Ophthalmology 2007; 114: 507-19, 524.
3. McAllister IL, Constable IJ. Laser-induced chorioretinal venous anastomosis for treatment of nonischemic central retinal vein occlusion. Arch Ophthalmol 1995; 113: 456-62.
4. Fekrat S, Goldberg MF, Finkelstein D. Laser-induced chorioretinal venous anastomosis for nonischemic central or branch retinal vein occlusion. Arch Ophthalmol 1998; 116: 43-52.
5. McAllister IL, Douglas JP, Constable IJ, Yu DY. Laser-induced chorioretinal venous anastomosis for nonischemic central retinal vein occlusion: Evaluation of the complications and their risk factors. Am J Ophthalmol 1998; 126: 219-29.
6. No authors listed. Baseline and early natural history report. The Central Vein Occlusion Study. Arch Ophthalmol 1993; 111: 1087-95.
7. Shima DT, Adamis AP, Ferrara N et al. Hypoxic induction of endothelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995; 1: 182-93.
8. Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GY. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Invest Ophthalmol Vis Sci 2000; 41: 2115-19.
9. Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, Jorge R. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008; 86: 385-9.
10. McAllister IL, Yu DY, Vijayasekaran S, Barry C, Constable I. Induced chorioretinal venous anastomosis in experimental retinal branch vein occlusion. Br J Ophthalmol 1992; 76: 615-20.
11. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36: 336-9.
12. Kriechbaum K, Michels S, Prager F et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: A prospective study. Br J Ophthalmol 2008; 92: 518-22.